Head to Head Review: Design Therapeutics (NASDAQ:DSGN) and Nautilus Biotechnology (NASDAQ:NAUT)

Nautilus Biotechnology (NASDAQ:NAUT) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Nautilus Biotechnology has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Earnings & Valuation

This table compares Nautilus Biotechnology and Design Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59.00 million	($0.46)	-4.13
Design Therapeutics	N/A	N/A	-$69.79 million	($1.20)	-12.85

Design Therapeutics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nautilus Biotechnology and Design Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Design Therapeutics	N/A	-33.07%	-31.29%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nautilus Biotechnology and Design Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1	0	1	0	2.00
Design Therapeutics	1	0	6	1	2.88

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 110.53%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 7.00%. Given Nautilus Biotechnology’s higher probable upside, equities research analysts clearly believe Nautilus Biotechnology is more favorable than Design Therapeutics.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Design Therapeutics

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.